Sera PrognosticsNASDAQ: SERA

SALT LAKE CITY , May 28, 2024 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another step forward for Sera during a year in which we expect to achieve several milestones in advancing our role as 'The pregnancy company' to improve maternal and neonatal healthcare outcomes," said Zhenya Lindgardt, President and CEO of Sera Prognostics.

SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., known as The Pregnancy Company® (NASDAQ: SERA), which aims to enhance maternal and neonatal health through cutting-edge pregnancy biomarker information for healthcare providers and patients, will release its first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after market close. A conference call and live webcast will be held at 5:00 p.m. to review operational achievements, financial outcomes, and important subjects.

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sera Prognostics specializes in women's health diagnostics with its PreTRM test, offering personalized risk assessment for preterm birth. The PreTRM test analyzes specific proteins and gestational age to provide accurate risk assessment for preterm birth. Sera Prognostics specializes in women's health through its flagship product, PreTRM, with an 88% sensitivity for predicting preterm births.

Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago.

SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amid another soft session on Wall Street, Sera Prognostics (NASDAQ: SERA ) — a specialist in the field of maternal and neonatal health — shook up the market with a dramatic increase in value. Fueling the blistering ride was encouraging data for its clinical study regarding risk assessment of premature delivery.